High

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colorectal Adenocarcinoma1
BRAF V600E AND MSI High	(prognostic)	Prognostic	B	Supports Poor Outcome	2	accepted	EID1940 In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC) PMID 27302369 · Schell et al., 2016 · Open in CIViC	civic
Endometrial Carcinoma1
MSI High	Pembrolizumab	Predictive	B	Supports Sensitivity Response	4	submitted	EID12364 A phase 3 randomized trial evaluated pembrolizumab (+ adjuvant chemotherapy) vs. placebo (+ adjuvant chemotherapy) in 1,095 newly diagnosed high-risk (non-endometrioid histology with FIGO stage I/II; … (full text at CIViC) PMID 39284383 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Colorectal Adenocarcinoma1

BRAF V600E AND MSI High

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID1940

In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC)

PMID 27302369 · Schell et al., 2016 · Open in CIViC

civic

Endometrial Carcinoma1

MSI High

Pembrolizumab

Predictive

Supports Sensitivity Response

submitted

EID12364

A phase 3 randomized trial evaluated pembrolizumab (+ adjuvant chemotherapy) vs. placebo (+ adjuvant chemotherapy) in 1,095 newly diagnosed high-risk (non-endometrioid histology with FIGO stage I/II; … (full text at CIViC)

PMID 39284383 ·

Malignant Colorectal Neoplasm4
MSI High	(prognostic)	Prognostic	B	Supports Better Outcome	3	submitted	EID12039 This study looked specifically at the prognostic significance of Microsatellite Instability High (MSI-H) in sporadic Australian Clinico Pathological Stage C colorectal cancer in patients from a single… (full text at CIViC) PMID 10971428 · Wright et al., 2000 · Open in CIViC	civic
MSI High	Ipilimumab/Nivolumab Regimen	Predictive	A	Supports Sensitivity Response	4	accepted	EID12561 In the phase III randomized open-label CheckMate 8HW trial (NCT04008030; n = 303, 255 centrally confirmed MSI-H/dMMR metastatic colorectal cancer), nivolumab plus ipilimumab significantly improved pro… (full text at CIViC) PMID 39602630 · Andre et al., 2024 · Open in CIViC	civic
MSI High	Ipilimumab/Nivolumab Regimen	Predictive	A	Supports Sensitivity Response	4	accepted	EID12562 In the phase III randomized open-label CheckMate 8HW trial (NCT04008030; n = 707 randomized; centrally confirmed MSI-H/dMMR: n = 296 nivolumab+ipilimumab vs 286 nivolumab) showed nivolumab plus ipilim… (full text at CIViC) PMID 39874977 · André et al., 2025 · Open in CIViC	civic
MSI High AND ( B2M Mutation OR JAK1 Mutation OR JAK2 Mutation )	Anti-PD1 Monoclonal Antibody	Predictive	B	Supports Sensitivity Response	2	submitted	EID12150 Thirty-five MSI-H/dMMR patients were treated with anti-PD-1 therapy. Of the 35 patients, 10 patients harboured B2M mutations, and 8 patients harboured JAK mutations. A low TMB score was noted in patie… (full text at CIViC) PMID 35343934 · Zhang et al., 2022 · Open in CIViC	civic

Malignant Colorectal Neoplasm4

MSI High

(prognostic)

Prognostic

Supports Better Outcome

submitted

EID12039

This study looked specifically at the prognostic significance of Microsatellite Instability High (MSI-H) in sporadic Australian Clinico Pathological Stage C colorectal cancer in patients from a single… (full text at CIViC)

PMID 10971428 · Wright et al., 2000 · Open in CIViC

civic

MSI High

Ipilimumab/Nivolumab Regimen

Predictive

Supports Sensitivity Response

accepted

EID12561

In the phase III randomized open-label CheckMate 8HW trial (NCT04008030; n = 303, 255 centrally confirmed MSI-H/dMMR metastatic colorectal cancer), nivolumab plus ipilimumab significantly improved pro… (full text at CIViC)

PMID 39602630 · Andre et al., 2024 · Open in CIViC

civic

MSI High

Ipilimumab/Nivolumab Regimen

Predictive

Supports Sensitivity Response

accepted

EID12562

In the phase III randomized open-label CheckMate 8HW trial (NCT04008030; n = 707 randomized; centrally confirmed MSI-H/dMMR: n = 296 nivolumab+ipilimumab vs 286 nivolumab) showed nivolumab plus ipilim… (full text at CIViC)

PMID 39874977 · André et al., 2025 · Open in CIViC

civic

MSI High AND ( B2M Mutation OR JAK1 Mutation OR JAK2 Mutation )

Anti-PD1 Monoclonal Antibody

Predictive

Supports Sensitivity Response

submitted

EID12150

Thirty-five MSI-H/dMMR patients were treated with anti-PD-1 therapy. Of the 35 patients, 10 patients harboured B2M mutations, and 8 patients harboured JAK mutations. A low TMB score was noted in patie… (full text at CIViC)

PMID 35343934 · Zhang et al., 2022 · Open in CIViC

civic

Malignant Endometrial Neoplasm2
MSI High	Carboplatin + Dostarlimab + PaclitaxelCombination	Predictive	B	Supports Sensitivity Response	5	submitted	EID12341 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 36972026 · Mirza et al., 2023 · Open in CIViC	civic
MSI High	Carboplatin + Dostarlimab + PaclitaxelCombination	Predictive	B	Supports Sensitivity Response	5	submitted	EID12343 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 38866180 · Powell et al., 2024 · Open in CIViC	civic

Malignant Endometrial Neoplasm2

MSI High

Carboplatin + Dostarlimab + PaclitaxelCombination

Predictive

Supports Sensitivity Response

submitted

EID12341

A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC)

PMID 36972026 · Mirza et al., 2023 · Open in CIViC

civic

MSI High

Carboplatin + Dostarlimab + PaclitaxelCombination

Predictive

Supports Sensitivity Response

submitted

EID12343

PMID 38866180 · Powell et al., 2024 · Open in CIViC

civic

Malignant Prostate Neoplasm1
MSI High	Immune Checkpoint Inhibitor	Predictive	B	Supports Sensitivity Response	4	submitted	EID12987 The molecular differences between MSI-H/dMMR and TMB-H/MSS prostate cancer were studied for the impact of these differences on immune checkpoint blockade (ICB) sensitivity. MSI and TMB were studied to… (full text at CIViC) PMID 38949888 · Lenis et al., 2024 · Open in CIViC	civic

Malignant Prostate Neoplasm1

MSI High

Immune Checkpoint Inhibitor

Predictive

Supports Sensitivity Response

submitted

EID12987

The molecular differences between MSI-H/dMMR and TMB-H/MSS prostate cancer were studied for the impact of these differences on immune checkpoint blockade (ICB) sensitivity. MSI and TMB were studied to… (full text at CIViC)

PMID 38949888 · Lenis et al., 2024 · Open in CIViC

civic

Rectal Carcinoma1
MSI High	Dostarlimab	Predictive	B	Supports Sensitivity Response	4	submitted	EID12368 47 patients with locally advanced rectal cancer were treated with dostarlimab. 41 completed treatment and achieved a clinical complete response. No patients experienced local or distant disease recurr… (full text at CIViC) Open in CIViC	civic

Rectal Carcinoma1

MSI High

Dostarlimab

Predictive

Supports Sensitivity Response

submitted

EID12368

47 patients with locally advanced rectal cancer were treated with dostarlimab. 41 completed treatment and achieved a clinical complete response. No patients experienced local or distant disease recurr… (full text at CIViC)

Open in CIViC

civic

Evidence by cancer (10 items)

Clinical significance (0)